| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1862 | 2020 |
| T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 … PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ... Journal of Clinical Oncology 37 (4), 318-327, 2019 | 771 | 2019 |
| Autophagy, metabolism, and cancer E White, JM Mehnert, CS Chan Clinical cancer research 21 (22), 5037-5046, 2015 | 688 | 2015 |
| Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ... JAMA oncology 2 (2), 234-240, 2016 | 630 | 2016 |
| Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study PA Ott, E Elez, S Hiret, DW Kim, A Morosky, S Saraf, B Piperdi, ... Journal of Clinical Oncology 35 (34), 3823-3829, 2017 | 527 | 2017 |
| Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study PA Ott, YJ Bang, D Berton-Rigaud, E Elez, MJ Pishvaian, HS Rugo, ... Journal of Clinical Oncology 35 (22), 2535-2541, 2017 | 466 | 2017 |
| Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study C Hsu, SH Lee, S Ejadi, C Even, RB Cohen, C Le Tourneau, JM Mehnert, ... Journal of Clinical Oncology 35 (36), 4050-4056, 2017 | 423 | 2017 |
| Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer JM Mehnert, A Panda, H Zhong, K Hirshfield, S Damare, K Lane, L Sokol, ... The Journal of clinical investigation 126 (6), 2334-2340, 2016 | 371 | 2016 |
| Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies HC Chung, SA Piha-Paul, J Lopez-Martin, JHM Schellens, S Kao, ... Journal of Thoracic Oncology 15 (4), 618-627, 2020 | 317 | 2020 |
| Autophagy maintains tumour growth through circulating arginine L Poillet-Perez, X Xie, LE Zhan, Y Yang, DW Sharp, ZS Hu, X Su, ... Nature 563 (7732), 569-573, 2018 | 298 | 2018 |
| Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028 A Varga, S Piha-Paul, PA Ott, JM Mehnert, D Berton-Rigaud, A Morosky, ... Gynecologic oncology 152 (2), 243-250, 2019 | 237 | 2019 |
| Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma X Xie, JY Koh, S Price, E White, JM Mehnert Cancer discovery 5 (4), 410-423, 2015 | 206 | 2015 |
| Immune activation and benefit from avelumab in EBV-positive gastric cancer A Panda, JM Mehnert, KM Hirshfield, G Riedlinger, S Damare, ... JNCI: Journal of the National Cancer Institute 110 (3), 316-320, 2018 | 189 | 2018 |
| Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. A Varga, SA Piha-Paul, PA Ott, JM Mehnert, D Berton-Rigaud, ... Journal of Clinical Oncology 33 (15_suppl), 5510-5510, 2015 | 187 | 2015 |
| Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial SP D'Angelo, S Bhatia, AS Brohl, O Hamid, JM Mehnert, P Terheyden, ... Journal for immunotherapy of cancer 8 (1), 2020 | 181 | 2020 |
| Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma X Xie, EP White, JM Mehnert PloS one 8 (1), e55096, 2013 | 178 | 2013 |
| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer JM Mehnert, A Varga, MS Brose, RR Aggarwal, CC Lin, A Prawira, ... BMC cancer 19, 1-9, 2019 | 175 | 2019 |
| Histone deacetylase inhibitors: biology and mechanism of action JM Mehnert, WK Kelly The Cancer Journal 13 (1), 23-29, 2007 | 161 | 2007 |
| First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors MN Stein, JR Bertino, HL Kaufman, T Mayer, R Moss, A Silk, N Chan, ... Clinical cancer research 23 (15), 4163-4169, 2017 | 150 | 2017 |
| Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers M Palmeri, J Mehnert, AW Silk, SK Jabbour, S Ganesan, P Popli, ... ESMO open 7 (1), 100336, 2022 | 142 | 2022 |
